Tellgen Corp
300642
Company Profile
Business description
Tellgen Corp manufactures and distributes in vitro diagnostic devices for detection of tumor. Its products include tumor marker, human papillomavirus, real time PCR, DNA methylation, autoimmune antibody, infectious disease and others. The company has developed products in the fields of tumor detection, cervical cancer screening, DNA methylation detection, male infertility and prenatal and postnatal care. Its products include tumor marker series products, human papillomavirus series products, Y chromosome microdeletion detection products, real time PCR, autoimmune antibody, and others.
Contact
No. 412 Huiqing Road
Pudong New District
Shanghai201201
CHNT: +86 2150495115
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2026
Employees
522
Stocks News & Analysis
stocks
Alphabet earnings: Continued momentum on cloud and search as capital expenses set to mount
Strong fourth quarter earnings.
stocks
Eli Lilly earnings: Revenue increases reflect global demand for oral obesity therapies
We’ve raised our fair value estimate of Lilly stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,154.90 | 49.70 | -0.54% |
| CAC 40 | 8,238.17 | 23.99 | -0.29% |
| DAX 40 | 24,491.06 | 111.98 | -0.46% |
| Dow JONES (US) | 49,023.30 | 217.69 | -0.44% |
| FTSE 100 | 10,309.22 | 93.12 | -0.90% |
| HKSE | 26,885.24 | 37.92 | 0.14% |
| NASDAQ | 22,622.48 | 632.71 | -2.72% |
| Nikkei 225 | 53,818.04 | 475.32 | -0.88% |
| NZX 50 Index | 13,444.02 | 23.27 | -0.17% |
| S&P 500 | 6,813.59 | 69.13 | -1.00% |
| S&P/ASX 200 | 8,889.20 | 38.60 | -0.43% |
| SSE Composite Index | 4,075.92 | 26.29 | -0.64% |